Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab + ICE for Relapsed/Refractory Hodgkin Lymphoma
NCT03077828Phase 2Unknown
- Sponsor
- Northwestern University
- Start
- Apr 2017
- Primary completion
- Dec 2020
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab in Hodgkin lymphoma (HL), sponsored by Northwestern University. Primary endpoint: Complete Response Rate up to 59 days. Status: unknown.
02
Drugs
03
Conditions
Hodgkin lymphoma (HL)
Beyond the preview
Go deeper on NCT03077828.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03077828.